Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad... Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Mehr anzeigen
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today...
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE...
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -1.84696569921 | 3.79 | 3.82 | 3.175 | 1326113 | 3.49014801 | CS |
| 4 | -0.61 | -14.0877598152 | 4.33 | 4.42 | 3.175 | 795871 | 3.84391882 | CS |
| 12 | -0.88 | -19.1304347826 | 4.6 | 4.7999 | 3.175 | 747073 | 4.13170701 | CS |
| 26 | 0.69 | 22.7722772277 | 3.03 | 5.02 | 2.875 | 952991 | 4.00481252 | CS |
| 52 | 1.41 | 61.038961039 | 2.31 | 5.02 | 1.86 | 1122595 | 3.5302609 | CS |
| 156 | 1.71 | 85.0746268657 | 2.01 | 5.02 | 0.301 | 1420058 | 1.86051659 | CS |
| 260 | 1.17 | 45.8823529412 | 2.55 | 5.02 | 0.301 | 1254512 | 2.30716386 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
